PHIO
Phio Pharmaceuticals Corp.
NASDAQ · Healthcare · Biotechnology · US
$0.87
−0.25%Oct 13, 2026, 11:00 UTC
Phio Pharmaceuticals announced successful completion of its first commercial-scale cGMP batch of PH-762 drug substance.
Source:Oct 5, 2026, 11:00 UTC
Phio Pharmaceuticals announced it accepted an invitation to present its INTASYL siRNA therapeutic platform and PH-762 program update at the National Investment Banking Association's 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida.
Source:Sep 28, 2026, 20:17 UTC
Phio Pharmaceuticals Corp. appointed Robert J. Bitterman as President & Chief Executive Officer.
Sep 28, 2026, 20:17 UTC
Phio Pharmaceuticals Corp. elected Robert J. Bitterman, Patricia A. Bradford, David H. Deming, Jonathan E. Freeman, Curtis A. Lockshin and R. Todd Plott to its board of directors effective September 28, 2026.
Sep 23, 2026, 11:00 UTC
Phio Pharmaceuticals announced it will present a clinical development update on PH-762 in cutaneous squamous cell carcinoma at the Life Sciences Future 2026 Conference on September 30 to October 1, 2026, in King of Prussia, Pennsylvania.
Source:Sep 14, 2026, 11:00 UTC
Phio Pharmaceuticals Corp. announced a key development milestone for PH-762, submitting a filing to the FDA to support the next stage of clinical development in cutaneous squamous cell carcinoma.
Source:Jul 21, 2026, 00:00 UTC
Phio Pharmaceuticals Corp. appointed R. Todd Plott, M.D. as a member of its Board of Directors and the Governance Committee, effective July 20, 2026.
Jun 24, 2026, 11:00 UTC
Phio Pharmaceuticals commenced first commercial-scale cGMP production of its lead candidate PH-762 drug substance at Nitto Denko Avecia.
Source: